Nephros (NEPH) Stock Price, News & Analysis

Company Overview

Nephros, Inc., a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also manufactures and sells water filters that enhance the taste and odor of water, as well as reduce biofilm, cysts, particulates, and scale build-up in downstream equipment. It markets its products to food service, hospitality, convenience store, and health care markets, as well as medical institutions. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.

Key Stats

• Today's Range: $3.45 to $5.00
• 50-Day Range: $1.80 to $5.00
• 52-Week Range: $1.36 to $5.00
• Volume: 218,207 shs
• Average Volume: 15,909 shs
• Market Capitalization: $53 million
• P/E Ratio: 71.44
• Dividend Yield: N/A
• Price Target: $5.00
• Consensus Rating: Buy

Nephros Stock Analysis - MarketRank™

Nephros scored higher than 7% of companies evaluated by MarketBeat, and ranked 899th out of 924 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.5 / 5
• Analyst Rating: Buy

Consensus Rating

Nephros has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Nephros has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Nephros is 71.44, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 23.55.

Price to Earnings Ratio vs. Sector

The P/E ratio of Nephros is 71.44, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 25.88.

Price to Book Value per Share Ratio

Nephros has a P/B Ratio of 6.17. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.06% of the float of Nephros has been sold short.

Short Interest Ratio / Days to Cover

Nephros has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Nephros has recently increased by 59.38%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Nephros does not currently pay a dividend.

Dividend Growth

Nephros does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.06% of the float of Nephros has been sold short.

Short Interest Ratio / Days to Cover

Nephros has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Nephros has recently increased by 59.38%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Nephros this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Nephros insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 6.70% of the stock of Nephros is held by insiders.

Percentage Held by Institutions

41.10% of the stock of Nephros is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

NEPH Stock Analysis - Frequently Asked Questions

How have NEPH shares performed this year?

Nephros' stock was trading at $1.47 at the start of the year. Since then, NEPH stock has increased by 240.1% and is now trading at $5.00.
View the best growth stocks for 2025 here.

How were Nephros' earnings last quarter?

Nephros Inc. (NASDAQ:NEPH) issued its quarterly earnings data on Thursday, May, 15th. The company reported $0.05 EPS for the quarter, topping the consensus estimate of ($0.01) by $0.06. The firm had revenue of $4.88 million for the quarter, compared to the consensus estimate of $3.67 million. Nephros had a net margin of 5.16% and a trailing twelve-month return on equity of 9.43%.

Who are Nephros' major shareholders?

Nephros' top institutional shareholders include Bard Associates Inc. (1.35%). Insiders that own company stock include Arthur H Amron and Robert R Jr Banks.
View institutional ownership trends.

How do I buy shares of Nephros?

Shares of NEPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Nephros own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Nephros investors own include NVIDIA (NVDA), Broadcom (AVGO), e.l.f. Beauty (ELF), Jabil (JBL), Arista Networks (ANET), Disc Medicine (IRON) and Novo Nordisk A/S (NVO).

Company Calendar

• Last Earnings: 5/15/2025
• Today: 6/23/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:NEPH
• CIK: 1196298
• Web: www.nephros.com
• Phone: (201) 343-5202
• Fax: 201-343-5207
• Employees: 30
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $5.00
• High Stock Price Target: $5.00
• Low Stock Price Target: $5.00
• Potential Upside/Downside: 0.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $0.07
• Trailing P/E Ratio: 71.44
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $70 thousand
• Net Margins: 5.16%
• Pretax Margin: 5.26%
• Return on Equity: 9.43%
• Return on Assets: 7.20%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.92
• Quick Ratio: 4.64

Sales & Book Value

• Annual Sales: $14.16 million
• Price / Sales: 3.74
• Cash Flow: $0.02 per share
• Price / Cash Flow: 249.86
• Book Value: $0.81 per share
• Price / Book: 6.17

Miscellaneous

• Outstanding Shares: 10,600,000
• Free Float: 9,890,000
• Market Cap: $53 million
• Optionable: Not Optionable
• Beta: 0.96